149 related articles for article (PubMed ID: 37536959)
1. Negative myoclonus causes locomotory disability in progressive myoclonus epilepsy type EPM1- Unverricht-Lundborg disease.
Vogt H; Baisch T; Mueller-Pfeiffer C; Mothersill IW
Epileptic Disord; 2023 Jun; 25(3):297-308. PubMed ID: 37536959
[TBL] [Abstract][Full Text] [Related]
2. Refining the phenotype of Unverricht-Lundborg disease (EPM1): a population-wide Finnish study.
Hyppönen J; Äikiä M; Joensuu T; Julkunen P; Danner N; Koskenkorva P; Vanninen R; Lehesjoki AE; Mervaala E; Kälviäinen R
Neurology; 2015 Apr; 84(15):1529-36. PubMed ID: 25770194
[TBL] [Abstract][Full Text] [Related]
3. Unverricht-Lundborg disease.
Crespel A; Ferlazzo E; Franceschetti S; Genton P; Gouider R; Kälviäinen R; Korja M; Lehtinen MK; Mervaala E; Simonato M; Vaarmann A
Epileptic Disord; 2016 Sep; 18(S2):28-37. PubMed ID: 27582036
[TBL] [Abstract][Full Text] [Related]
4. Alterations of motor cortical excitability and anatomy in Unverricht-Lundborg disease.
Danner N; Julkunen P; Hyppönen J; Niskanen E; Säisänen L; Könönen M; Koskenkorva P; Vanninen R; Kälviäinen R; Mervaala E
Mov Disord; 2013 Nov; 28(13):1860-7. PubMed ID: 23925991
[TBL] [Abstract][Full Text] [Related]
5. Molecular background of EPM1-Unverricht-Lundborg disease.
Joensuu T; Lehesjoki AE; Kopra O
Epilepsia; 2008 Apr; 49(4):557-63. PubMed ID: 18028412
[TBL] [Abstract][Full Text] [Related]
6. Severer phenotype in Unverricht-Lundborg disease (EPM1) patients compound heterozygous for the dodecamer repeat expansion and the c.202C>T mutation in the CSTB gene.
Koskenkorva P; Hyppönen J; Aikiä M; Mervaala E; Kiviranta T; Eriksson K; Lehesjoki AE; Vanninen R; Kälviäinen R
Neurodegener Dis; 2011; 8(6):515-22. PubMed ID: 21757863
[TBL] [Abstract][Full Text] [Related]
7. Clinical picture of EPM1-Unverricht-Lundborg disease.
Kälviäinen R; Khyuppenen J; Koskenkorva P; Eriksson K; Vanninen R; Mervaala E
Epilepsia; 2008 Apr; 49(4):549-56. PubMed ID: 18325013
[TBL] [Abstract][Full Text] [Related]
8. Unverricht-Lundborg progressive myoclonus epilepsy in Oman.
Santoshkumar B; Turnbull J; Minassian BA
Pediatr Neurol; 2008 Apr; 38(4):252-5. PubMed ID: 18358403
[TBL] [Abstract][Full Text] [Related]
9. Genetic testing and the phenotype of Polish patients with Unverricht-Lundborg disease (EPM1) - A cohort study.
Bosak M; Sułek A; Łukasik M; Żak A; Słowik A; Lasek-Bal A
Epilepsy Behav; 2020 Nov; 112():107439. PubMed ID: 32920378
[TBL] [Abstract][Full Text] [Related]
10. The Roles of Cystatin B in the Brain and Pathophysiological Mechanisms of Progressive Myoclonic Epilepsy Type 1.
Singh S; Hämäläinen RH
Cells; 2024 Jan; 13(2):. PubMed ID: 38247861
[TBL] [Abstract][Full Text] [Related]
11. Cognitive functioning in progressive myoclonus epilepsy type 1 (Unverricht-Lundborg Disease, EPM1).
Äikiä M; Hyppönen J; Mervaala E; Kälviäinen R
Epilepsy Behav; 2021 Sep; 122():108157. PubMed ID: 34171687
[TBL] [Abstract][Full Text] [Related]
12. Electroclinical presentation and genotype-phenotype relationships in patients with Unverricht-Lundborg disease carrying compound heterozygous CSTB point and indel mutations.
Canafoglia L; Gennaro E; Capovilla G; Gobbi G; Boni A; Beccaria F; Viri M; Michelucci R; Agazzi P; Assereto S; Coviello DA; Di Stefano M; Rossi Sebastiano D; Franceschetti S; Zara F
Epilepsia; 2012 Dec; 53(12):2120-7. PubMed ID: 23205931
[TBL] [Abstract][Full Text] [Related]
13. Detecting negative myoclonus during long-term home measurements using wearables.
Sinokki A; Säisänen L; Hyppönen J; Silvennoinen K; Kälviäinen R; Mervaala E; Karjalainen PA; Rissanen SM
Clin Neurophysiol; 2023 Dec; 156():166-174. PubMed ID: 37952446
[TBL] [Abstract][Full Text] [Related]
14. Cystatin B: mutation detection, alternative splicing and expression in progressive myclonus epilepsy of Unverricht-Lundborg type (EPM1) patients.
Joensuu T; Kuronen M; Alakurtti K; Tegelberg S; Hakala P; Aalto A; Huopaniemi L; Aula N; Michellucci R; Eriksson K; Lehesjoki AE
Eur J Hum Genet; 2007 Feb; 15(2):185-93. PubMed ID: 17003839
[TBL] [Abstract][Full Text] [Related]
15. A novel c132-134del mutation in Unverricht-Lundborg disease and the review of literature of heterozygous compound patients.
Assenza G; Benvenga A; Gennaro E; Tombini M; Campana C; Assenza F; Di Pino G; Di Lazzaro V
Epilepsia; 2017 Feb; 58(2):e31-e35. PubMed ID: 27888502
[TBL] [Abstract][Full Text] [Related]
16. Abnormal microglial activation in the Cstb(-/-) mouse, a model for progressive myoclonus epilepsy, EPM1.
Okuneva O; Körber I; Li Z; Tian L; Joensuu T; Kopra O; Lehesjoki AE
Glia; 2015 Mar; 63(3):400-11. PubMed ID: 25327891
[TBL] [Abstract][Full Text] [Related]
17. Abnormal motor cortical adaptation to external stimulus in Unverricht-Lundborg disease (progressive myoclonus type 1, EPM1).
Julkunen P; Löfberg O; Kallioniemi E; Hyppönen J; Kälviäinen R; Mervaala E
J Neurophysiol; 2018 Aug; 120(2):617-623. PubMed ID: 29742025
[TBL] [Abstract][Full Text] [Related]
18. Altered cortical inhibition in Unverricht-Lundborg type progressive myoclonus epilepsy (EPM1).
Danner N; Julkunen P; Khyuppenen J; Hukkanen T; Könönen M; Säisänen L; Koskenkorva P; Vanninen R; Lehesjoki AE; Kälviäinen R; Mervaala E
Epilepsy Res; 2009 Jul; 85(1):81-8. PubMed ID: 19321308
[TBL] [Abstract][Full Text] [Related]
19. Clinical and molecular characterization of Unverricht-Lundborg disease among Egyptian patients.
Hosny H; El Tamawy M; Gouider R; Lesca G; Abdel Naseer M; Kishk N; Abdel-Hamid MS; Ashmawi A
Epilepsy Res; 2021 Oct; 176():106746. PubMed ID: 34474241
[TBL] [Abstract][Full Text] [Related]
20. Insights into the Genetic Profile of Two Siblings Affected by Unverricht-Lundborg Disease Using Patient-Derived hiPSCs.
Lucchino V; Scaramuzzino L; Scalise S; Lo Conte M; Zannino C; Benedetto GL; Aguglia U; Ferlazzo E; Cuda G; Parrotta EI
Cells; 2022 Nov; 11(21):. PubMed ID: 36359887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
